Purpose: To evaluate ischemic changes in brain magnetic resonance images in patients with pseudoexfoliation syndrome (PXS) and pseudoexfoliation glaucoma (PXG) and compare them with age- and sex-matched control subjects. Methods: This case-control study involved 16 consecutive patients with PXS, 21 patients with PXG and 18 healthy age- and sex-matched control subjects. Each subject underwent a comprehensive ophthalmological examination. In all participants, an axial T1-, T2- and proton-density-weighted and coronal cerebral 1.5-tesla magnetic resonance imaging (MRI) scan was made. White matter hyperintensities (WMH) were considered present if these were hyperintense on both proton-density- and T2-weighted images and not hypointense on T1-weighted images. White matter lesions were classified into two parts as the subcortical and periventricular regions. We used a validated rating scale of subcortical WMH: 0 = absent, 1 = punctuate foci, 2 = beginning confluence of foci and 3 = large confluent areas. Periventricular white matter lesions were classified on a scale of 0 (no white matter lesions), 1 (pencil-thin periventricular lining), 2 (thick lining) or 3 (large confluent white matter lesions). Results: The proportions of persons with WMH were 93.7% for patients with PXS, 95.2% for patients with PXG and 55.5% for control subjects. The numbers of white matter lesions in patients with PXS and PXG were significantly greater than in the control subjects (p < 0.05). White matter lesions at subcortical locations in patients with PXG were significantly more frequent than in the control subjects (80.9 vs. 33.3%; p < 0.05). The proportion of patients with subcortical WMH was 56.2% in PXS; no significant difference was found in subcortical WMH between PXS and controls. The proportions of patients with periventricular WMH were 93% in PXS, 90.4% in PXG and 44.4% in controls. White matter lesions at periventricular locations in patients with PXG and PXS were significantly more frequent than in the control subjects (p < 0.05). The difference between the pseudoexfoliation groups and controls with regard to the size of periventricular and subcortical white matter lesions was statically significant (p < 0.05). When patients with PXS were compared with PXG patients, there was no statistically significant difference in the number, size and scale of white matter lesions. Conclusion: We found a significantly higher prevalence of MRI-defined WMH in patients with a clinical diagnosis of pseudoexfoliation with or without glaucoma versus control subjects. We think that the findings in this study may shed light on a possible link between ischemic brain lesions and pseudoexfoliation, which is not related with the presence of glaucomatous optic neuropathy. Further investigations are required to resolve the underlying associations.

Keywords:
Brain magnetic resonance imaging, Glaucoma, Pseudoexfoliation, White matter hyperintensities
1.
Ritch R, Schlötzer-Schrehardt U: Exfoliation syndrome. Surv Ophthalmol 2001;45:265–315.
2.
Asano N, Schlötzer-Schrehardt U, Naumann GOH: A histopathologic study of iris changes in pseudoexfoliation syndrome. Ophthalmology 1995;102:1279–1290.
3.
Helbig H, Schlötzer-Schrehardt U, Noske W, Kellner U, Foerster MH, Naumann GOH: Anterior-chamber hypoxia and iris vasculopathy in pseudoexfoliation syndrome. Ger J Ophthalmol 1994;3:148–153.
4.
Khalil AK, Kuboto T, Tawara A, Inomata H: Early changes in iris blood vessels in exfoliation syndrome. Curr Eye Res 1998;17:1124–1134.
5.
Cursiefen C, Hammer T, Küchle M, Naumann GOH, Schlötzer-Schrehardt U: Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion: a histopathologic and electron microscopic study. Acta Ophthalmol Scand 2001;79:476–478.
6.
Naumann GOH, Schlötzer-Schrehardt U, Küchle M: Pseudoexfoliation syndrome for the comprehensive ophthalmologist: intraocular and systemic manifestations. Ophthalmology 1998;105:951–968.
7.
Schlötzer-Schrehardt U, Koca MH, Naumann GOH, Volkholz H: Pseudoexfoliation syndrome: ocular manifestation of a systemic disorder? Arch Ophthalmol 1992;110:1752–1756.
8.
Schlötzer-Schrehardt U, Küchle M, Naumann GOH: Electron-microscopic identification of pseudoexfoliation material in extrabulbar tissue. Arch Ophthalmol 1991;109:565–570.
9.
Streeten BW, Dark AJ, Wallace RN, Li ZY, Hoepner JA: Pseudoexfoliative fibrillopathy in the skin of patients with ocular pseudoexfoliation. Am J Ophthalmol 1990;110:490–499.
10.
Streeten BW, Li Z-Y, Wallace RN, Eagle RC, Keshgegian AA: Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol 1992;110:1757–1762.
11.
Li ZY, Streeten BW, Wallace RN: Association of elastin with pseudoexfoliative material: an immunoelectron microscopic study. Curr Eye Res 1988;7:1163–1172.
12.
Mitchell P, Wang JJ, Smith W: Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol 1997;124:685–687.
13.
Schumacher S, Schlötzer-Schrehardt U, Martus P, Lang W, Nauman GOH: Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet 2001;357:359–360.
14.
Repo LP, Terasvirta ME, Koivito KJ: Generalized transluminance of the iris and the frequency of the pseudoexfoliation syndrome in the eyes of transient ischemic attack patients. Ophthalmology 1993;100:352–355.
15.
Yüksel N, Karabaş L, Arslan A, Demirci A, Çağlar Y: Ocular hemodynamics in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Ophthalmology 2001;108:1043–1049.
16.
Yüksel N, Anık Y, Kılıç A, Karabaş VL, Çağlar Y, Demirci A: Cerebrovascular blood flow velocities in pseudoexfoliation. Graefes Arch Clin Exp Ophthalmol, in press.
17.
Linnér E, Popovic V, Gottfries C-G, Sjogren M, Wallin A: The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer’s type. Acta Ophthalmol Scand 2001;79:283–285.
18.
Ringvold A, Blika S, Sandvik L: Pseudoexfoliation and mortality. Acta Ophthalmol Scand 1997;75:255–256.
19.
Shrüm KR, Hattenhauer MG, Hodge D: Cardiovascular and cerebrovascular mortality associated with ocular pseudoexfoliation. Am J Ophthalmol 2000;129:83–86.
20.
Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H: Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals: correlations with plasma concentrations of naturally occurring antioxidants. Stroke 1996;27:2043–2047.
21.
Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H: Pathologic correlates of incidental white matter signal hyperintensities. Neurology 1993;43:1683–1689.
22.
Pantoni L: Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002;13(suppl 2):7–10.
23.
Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD: Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002;59:787–793.
24.
Kudo T, Imaizumi K, Tanimukai H, Katayama T, Sato N, Nakamura Y, Tanaka T, Kashiwagi Y, Jinno Y, Tohyama M, Takeda M: Are cerebrovascular factors involved in Alzheimer’s disease? Neurobiol Aging 2000;21:215–224.
25.
Onk K, Farinelli A, Billson F, Houang M, Stern M: Comparative study of brain magnetic resonance imaging findings in patients with low-tension glaucoma and control subjects. Ophthalmology 1995;102:1632–1638.
26.
Stroman GA, Stewart WC, Golnic KC, Cure JK, Olinger RE: Magnetic resonance imaging in patients with low tension glaucoma. Arch Ophthalmol 1995;113:168–172.
27.
Claus JJ, Breteler MMB, Hasan D, Krenning EP, Bots ML, Grobbee DE, Van Swieten JC, Harskamp FV, Hofman A: Regional cerebral blood flow and cerebrovascular risk factors in the elderly population. Neurobiol Aging 1998;19:57–64.
28.
Pantoni L, Garcia JH, Gutierrez JA: Cerebral white matter is highly vulnerable to ischemia. Stroke 1996;27:1641–1647.
29.
Puustjärvi T, Blomster H, Kontkanen M, Punnonen K, Teräsvirta M: Plasma and aqueous humour levels of homocysteine in exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol 2004;242:749–754.
30.
Tyagi SC: Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 1998;274:396–405.
31.
Eagle RC, Font RL, Fine BS: The basement membrane exfoliation syndrome. Arch Ophthalmol 1979;97:510–515.
32.
Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al: Plasma homocysteine: a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775–1781.
33.
Leibovitch I, Kurtz S, Shemesh G, Goldstein M, Sela B, Lazar M, Loewenstein A: Hyperhomocystinemia in pseudoexfoliation glaucoma. J Glaucoma 2003;12:36–38.
34.
Vermeer SE, van Dijk EJ, Koudstaal Pjreteler MM: Homocysteine levels, cerebrovascular risk factors, and cerebral white matter lesions. The Rotterdam Scan Study. Ann Neurol 2002;51:285–289.
35.
Vessani RM, Ritch R, Leibmann JM, Jofe M: Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol 2003;1:41–46.
36.
Bescond A, Augier T, Chareyre C, et al: Influence of homocysteine on matrix metalloproteinase 2: activation and activity. Biochem Biophys Res Commun 1999;263:498–503.
37.
Moore P, EL-Sherbeny A, Roon P, et al: Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res 2001;73:45–57.
38.
de Leeuw F-E, de Groot JC, Achten E, Oudkerk M, Ramos LMP, Heijboer R, Hofman A, Jolles J, Gijn J, Breteler MMB: Prevalence of cerebral white matter lesions in elderly people: a population-based magnetic resonance imaging study. The Rotterdam Scan Study J Neurol Neurosurg Psychiatry 2001;70:9–14.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.